Loading...
Bilateral Trade Intelligence · $25 Total Trade · 1 Foreign Suppliers · 1 Indian Buyers · DGFT Verified · Updated March 2026
India imported $25 worth of pharmaceutical formulations from Ethiopia across 2 verified shipments, from 1 foreign suppliers to 1 Indian buyers. The top suppliers are ARMAUER HANSEN RESEARCH INSTITUTE ($25). The leading products are Plasma ($25). Average shipment value: $12.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Plasma | $25 | 100.0% |
India imports 1+ pharmaceutical formulations from Ethiopia with a combined trade value of $25. Key products include Plasma ($25). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 2 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Ethiopia, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Ethiopia buyers, regulatory requirements, and logistics for that specific product corridor. Products include Plasma ($25) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Ethiopia. Leading exporters include Armauer Hansen Research Institute, . The top exporter accounts for 100.0% of total India–Ethiopia pharma exports. Source: Indian Customs (DGFT).
1 companies in Ethiopia import pharmaceutical formulations from India. Top buyers include Cliantha Research Limited, . The largest buyer accounts for 100.0% of India–Ethiopia pharma imports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Ethiopia and India has experienced modest activity from 2022 to 2026. Between 2022 and 2026, Ethiopia exported a total of $25 USD worth of finished pharmaceutical formulations to India, comprising two shipments. The sole supplier from Ethiopia during this period was the ARMAUER HANSEN RESEARCH INSTITUTE, which provided plasma products. The recipient in India was CLIANTHA RESEARCH LIMITED, which received both shipments. This limited trade volume indicates a nascent and underdeveloped trade relationship in the pharmaceutical sector between the two nations.
Ethiopia's contribution to India's pharmaceutical imports is negligible, accounting for only $25 USD over the 2022-2026 period. This minimal share underscores Ethiopia's limited presence in India's pharmaceutical import landscape. The sole product imported from Ethiopia was plasma, highlighting the narrow scope of pharmaceutical categories involved in this trade.
Between 2024 and 2026, there were no significant policy changes, trade agreements, or regulatory harmonization efforts between Ethiopia and India in the pharmaceutical sector. The trade volume remained static, indicating a lack of substantial developments in this bilateral corridor during the specified period.
Registration process, GMP requirements, import documentation
For Ethiopian companies aiming to export pharmaceutical products to India, obtaining registration with the Central Drugs Standard Control Organisation (CDSCO) is mandatory. The process involves several key steps:
1. Application Submission: Companies must register on the CDSCO SUGAM portal, providing details about the applicant and the products intended for import.
2. Document Submission: Essential documents include the Certificate of Pharmaceutical Product (COPP), Good Manufacturing Practice (GMP) certificate, free sale certificate, and a power of attorney.
3. Review and Approval: CDSCO reviews the application and may conduct inspections to ensure compliance with Indian standards.
4. License Issuance: Upon successful evaluation, CDSCO issues the necessary import license, authorizing the company to export pharmaceutical products to India.
The entire process can take several months, depending on the completeness of the application and the efficiency of the review process.
India requires that manufacturing sites in Ethiopia adhere to Good Manufacturing Practice (GMP) standards as per WHO guidelines. Ethiopian manufacturers must obtain WHO prequalification, which involves demonstrating compliance with international quality standards. CDSCO may conduct inspections to verify adherence to these standards before granting approval for importation into India.
To import pharmaceutical products into India, Ethiopian companies must provide:
Additionally, compliance with Indian customs procedures, including proper labeling and packaging, is essential for smooth importation.
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical imports from Ethiopia to India are limited to plasma products, with a total value of $25 USD over the 2022-2026 period. This singular product category indicates a lack of diversity in the types of pharmaceutical products imported from Ethiopia to India.
Given the minimal trade volume and limited product range, there is currently no significant importation of innovator drugs, novel formulations, or advanced therapies from Ethiopia to India. The trade is predominantly restricted to basic pharmaceutical products like plasma.
The negligible import volume from Ethiopia to India suggests that factors such as patent protection, technology gaps, quality requirements, and disease burden are not significant drivers for importing pharmaceutical products from Ethiopia. The limited trade may be attributed to other considerations, including cost-effectiveness and availability of alternative suppliers.
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes:
Specific duty rates and taxes depend on the product classification and prevailing government policies.
As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Ethiopia concerning pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations, but no bilateral agreements have been established to facilitate pharmaceutical trade.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and ensures that only genuine innovations receive patent protection. Compulsory licensing provisions allow the government to grant licenses to third parties under certain conditions, such as public health emergencies. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs, including imported pharmaceuticals, to ensure affordability and accessibility.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Ethiopia to India are typically transported via sea routes, with transit times varying based on the specific ports of departure and arrival. Air freight is also an option, offering faster delivery times but at higher costs. The reliability of these routes depends on factors such as weather conditions, geopolitical stability, and port efficiency.
Ethiopia's primary export ports include the Port of Djibouti, which handles a significant portion of the country's international trade. In India, major import ports include the Jawaharlal Nehru Port in Mumbai and the Chennai Port, both equipped to handle pharmaceutical shipments. The efficiency and capacity of these ports are crucial for the timely and safe delivery of pharmaceutical products.
Indian customs procedures for pharmaceutical imports involve:
Market size, healthcare system, growth outlook
Despite being a major pharmaceutical manufacturer, India imports certain specialized products, including plasma, to meet specific medical needs. The importation of plasma from Ethiopia may be driven by factors such as cost-effectiveness, availability, and the need to diversify sources.
As of March 2026, there are no significant Ethiopian pharmaceutical companies operating in India. The limited trade volume suggests that Ethiopian companies have not established a substantial presence in the Indian market.
India's Atmanirbhar Bharat initiative and the Production-Linked Incentive (PLI) scheme aim to boost domestic manufacturing and reduce import dependency. While these efforts may lead to increased self-reliance, the demand for specialized products like plasma may continue to necessitate imports from countries like Ethiopia.
Competing origins, India's edge, challenges and threats
India imports pharmaceutical products from various countries, including the USA, EU, China, Switzerland, and Japan. Ethiopia's share in this import landscape is minimal, with a total of $25 USD over the 2022-2026 period. This indicates that other countries are the primary suppliers of pharmaceutical products to India.
Ethiopian pharmaceutical products may offer competitive advantages such as cost-effectiveness and the ability to meet specific quality standards. However, the limited trade volume suggests that these advantages have not been fully realized in the Indian market.
Indian pharmaceutical manufacturers are continually developing alternatives to imported products, including
India exported pharmaceuticals worth $25 to Ethiopia across 2 verified shipments.
1. ARMAUER HANSEN RESEARCH INSTITUTE — $25. Total: 1 suppliers.
1. CLIANTHA RESEARCH LIMITED — $25. 1 buyers total.
1. Plasma ($25, 100.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $25 corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$12 per consignment across 2 shipments.
1 Indian companies. Largest: ARMAUER HANSEN RESEARCH INSTITUTE with $25.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 2 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists